Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus and Cixutumumab in Metastatic Sarcomas
NCT01016015Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2009
- Primary completion
- Jul 2014
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of cixutumumab, temsirolimus in soft tissue sarcoma (STS), bone sarcoma, osteosarcoma (OS), sponsored by National Cancer Institute. Started Nov 2009; status: completed.
02
Drugs
cixutumumabtemsirolimus
03
Conditions
soft tissue sarcoma (STS)bone sarcomaosteosarcoma (OS)
Beyond the preview
Go deeper on NCT01016015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01016015.